한국 의약품부작용보고원시자료를 활용한 알파차단제의 이상사례 실마리정보 비교 분석
Signal Detection of Alpha-adrenoceptor Antagonist using the KIDS-KAERS database (KIDS-KD)
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Using KIDS-KAERS database (KIDS-KD) from 2016 to 2020, the aim is to investigate signals of adverse events of alpha-adrenoceptor antagonists and to present adverse events that are not included in the precautions for use when marketing approval. Methods: This study was conducted by disproportionality analysis. Data mining analysis was performed to detect signals of alpha-adrenoceptor antagonists, such as terazosin, doxazosin, alfuzosin, silodosin, and tamsulosin. The signal was defined by three criteria as proportional reporting ratio (PRR), reporting odds ratio (ROR), and information component (IC). Detected signals were compared with product labeling and the European Medicines Agency-Important Medical Events list. Results: Out of the total number of 408,077 reports for adverse events, 6,750 cases were reported as adverse events of alpha-adrenoceptor antagonists. Dizziness, mouth dryness, hypotension postural, and oedema peripheral are identified as common adverse events of five alphaadrenoceptor antagonists and are typically listed on drug labels. However, new signals were detected for pneumonia, chronic obstructive airway disease, eye diseases such as glaucoma and cataracts, fracture, and ileus of tamsulosin that were not previously listed on the drug labels in Korea. Conclusions: This study identified signals related to adverse drug reactions of alpha-adrenoceptor antagonists and presented serious adverse events, suggesting new adverse reactions to be aware of when using alpha-adrenoceptor antagonists.
Abstract
Background: Using KIDS-KAERS database (KIDS-KD) from 2016 to 2020, the aim is to investigate signals of adverse events of alpha-adrenoceptor antagonists and to present adverse events that are not included in the precautions for use when marketing approval. Methods: This study was conducted by disproportionality analysis. Data mining analysis was performed to detect signals of alpha-adrenoceptor antagonists, such as terazosin, doxazosin, alfuzosin, silodosin, and tamsulosin. The signal was defined by three criteria as proportional reporting ratio (PRR), reporting odds ratio (ROR), and information component (IC). Detected signals were compared with product labeling and the European Medicines Agency-Important Medical Events list. Results: Out of the total number of 408,077 reports for adverse events, 6,750 cases were reported as adverse events of alpha-adrenoceptor antagonists. Dizziness, mouth dryness, hypotension postural, and oedema peripheral are identified as common adverse events of five alphaadrenoceptor antagonists and are typically listed on drug labels. However, new signals were detected for pneumonia, chronic obstructive airway disease, eye diseases such as glaucoma and cataracts, fracture, and ileus of tamsulosin that were not previously listed on the drug labels in Korea. Conclusions: This study identified signals related to adverse drug reactions of alpha-adrenoceptor antagonists and presented serious adverse events, suggesting new adverse reactions to be aware of when using alpha-adrenoceptor antagonists.
참고문헌 (33)
- Miernik A, "Current treatment for benign prostatic hyperplasia", Dtsch Arztebl Int, 117(49), pp.843~ (2020)
- Lerner LB, "Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia : Aua guideline part i—initial work-up and medical management", J Urol, 206(4), pp.806~817 (2021)
- Kim DK, "Changes in diagnosis rate and treatment trends of benign prostatic hyperplasia in Korea : A nationwide population-based cohort study", Prostate International, 9(4), pp.215~220 (2021)
- Del Giudice F, "Recent trends in the diagnostic and surgical management of benign prostatic hyperplasia in the us from 2004 to 2017 : Annual changes in the selection of treatment options and medical costs", Applied Sciences, 12(17), pp.8697~ (2022)
- Kumar V, "Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate", Int Urol Nephrol, 32(1), pp.67~71 (2000)
- Yu Z-W, "The efficacy and safety of alpha-adrenergic blockers for medical expulsion therapy in patients with ureteral calculi : A meta-analysis of placebo-controlled trials", Medicine(Baltimore), 100(37), pp.e27272~ (2021)
- Li H, "Role of α1-blockers in the current management of hypertension", J Clin Hypertens(Greenwich), 24(9), pp.1180~1186 (2022)
- Duan Y, "Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia", Pharmacoepidemiol Drug Saf, 27(3), pp.340~348 (2018)
- Latvala L, "Use of α1-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of alzheimer's disease", Pharmacoepidemiol Drug Saf, 31(10), pp.1110~1120 (2022)
- Inoue A, "Maculopapular type drug eruption caused by silodosin", Allergol Int, 65(2), pp.219~220 (2016)
- Klimi E, "A probable case of mucosal fixed drug eruption following treatment with silodosin", Sultan Qaboos Univ Med J, 18(3), pp.e402~ (2018)
- Yoshimura K, "A survey of the faers database concerning the adverse event profiles of α1-adrenoreceptor blockers for lower urinary tract symptoms", Int J Med Sci, 10(7), pp.864~ (2013)
- Ohyama K, "Evaluation of syncope association with α1-adrenoceptor blockers in males using the FAERS database:Impact of concomitant hypertension Pharmazie", 74(12), pp.755~759 (2019)
- Ohyama K, "Onset time profiles for syncope associated with α1-adrenoceptor blockers in males : Analysis of a spontaneous adverse drug event database", Pharmacology & Pharmacy, 9(12), pp.515~526 (2018)
- 장민교, "의약품부작용보고시스템을 이용한 바레니클린의 이상사례 실마리정보 도출", 한국임상약학회지, 32(1), pp.1~7 (2022), 한국임상약학회[DOI]
- "Inclusion/exclusion criteria for the “Important Medical Events” list"[URL]
- van Puijenbroek EP, "A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions", Pharmacoepidemiol Drug Saf, 11(1), pp.3~10 (2002)
- Evans SJ, "Use of proportional reporting ratios for signal generation from spontaneous adverse drug reaction reports", Pharmacoepidemiol Drug Saf, 10(6), pp.483~486 (2001)
- Shin JY, "New initiatives for pharmacovigilance in south korea : Introducing the korea institute of drug safety and risk management(kids)", Pharmacoepidemiol Drug Saf, 23(11), pp.1115~1122 (2014)
- "Medication Information Bulletin Board"[URL]
- Kaplan SA, "Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency", J Urol, 189(1), pp.S129~34 (2013)
- Nishizawa O, "Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics", Low Urin Tract Symptoms, 3(1), pp.29~35 (2011)
- McKiernan JM, "Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia", South Med J, 90(5), pp.509~513 (1997)
- Thomsen RW, "Association of α1-blocker receipt with 30-day mortality and risk of intensive care unit admission among adults hospitalized with influenza or pneumonia in Denmark", JAMA Netw Open, 4(2), pp.e2037053~ (2021)
- Sirak TE, "Therapeutic update : Non-selective beta-and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure", J Am Coll Cardiol, 44(3), pp.497~502 (2004)
- Smith MC, "Epidemiology and clinical impact of major comorbidities in patients with COPD", Int J Chron Obstruct Pulmon Dis, 1(1), pp.871~888 (2014)
- Raherison C, "Epidemiology of COPD", Eur Respir Rev, 18(114), pp.213~221 (2009)
- Welk B, "The risk of fall and fracture with the initiation of a prostate-selective α antagonist : A population based cohort study", BMJ, 351, pp.h5398~ (2015)
- 서기현, "Risk of Hip Fractures in Men with Alpha-Blockers: A Nationwide Study Base on Claim Registry", 대한골대사학회지, 22(1), pp.29~32 (2015), 대한골대사학회[DOI]
- Bonnell LN, "One-day postoperative intraocular pressure spikes after phacoemulsification cataract surgery in patients taking tamsulosin", J Cataract Refract Surg, 42(12), pp.1753~1758 (2016)
- Zheng W, "Systemic medication associations with presumed advanced or uncontrolled primary open-angle glaucoma", Ophthalmology, 125(7), pp.984~993 (2018)
- Lee JW, "Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma", Cutan Ocul Toxicol, 32(2), pp.182~184 (2013)
- Ghuman A, "Urinary retention in early urinary catheter removal after colorectal surgery", Am J Surg, 215(5), pp.949~952 (2018)